Alnylam Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.07.16	BIND Gallups On Stalking Horse Offer, KBIO Is Back, ALNY Abuzz (RTTNews)
01.07.16	Alnylam Reports Results From Phase 2 OLE Studies With Patisiran, Revusiran (RTTNews)
10.06.16	MRK Opens Wallet, VRX To Face FDA Panel In July, SPHS Vaults On Trial Data (RTTNews)
09.06.16	Alnylam Pharma Starts Phase 1 Clinical Trial For ALN-TTRsc02 - Quick Facts (RTTNews)
02.05.16	EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q1 Earnings Report (RTTNews)
20.04.16	Alnylam Reports Complete 18-month Data From Phase II OLE Study Of Patisiran (RTTNews)
11.02.16	EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q4 Earnings Report (RTTNews)
09.11.15	Alnylam Pharma Q3 Loss Widens, But Meets View - Quick Facts (RTTNews)
09.11.15	EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q3 Earnings Report (RTTNews)
03.11.15	Alnylam: Patisiran Has Potential To Halt Neuropathy Progression In FAP Patients (RTTNews)
01.10.15	Genzyme Opts Into Alnylam's ALN-AT3 Hemophilia Program - Quick Facts (RTTNews)
28.09.15	Alnylam, Collaborators Announce New Results From Phase 2 OLE Study Of Patisiran (RTTNews)
15.09.15	Alnylam Reports Initial Positive Results From ALN-AS1 Phase 1 Trial (RTTNews)
30.08.15	ALN-PCS Phase 1 Clinical Trial Shows Positive Results (RTTNews)
06.08.15	Alnylam Pharma Loss Wider Than Estimates (RTTNews)
06.08.15	EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q2 Earnings Report (RTTNews)
27.07.15	Alnylam Pharma Initiates Phase 1/2 Clinical Trial With ALN-AAT - Quick Facts (RTTNews)
15.06.15	CRBP Is One To Keep An Eye On, FDA Expands Use Of Promacta, OSUR Gets Funds (RTTNews)
21.05.15	ISR In All Its Radiance, GNCA's Herpes Drug Meets Trial Goal, AMAG On A High (RTTNews)
20.05.15	Alnylam Receives Orphan Drug Designation From FDA For Revusiran - Quick Facts (RTTNews)
18.05.15	MOH Opens Wallet, IMMU Fast Tracked, OVAS Continues To Deliver (RTTNews)
21.04.15	Alnylam Pharma's Patisiran Phase 2 Study Decreases Neuropathy Progression (RTTNews)
16.03.15	Alnylam Announces Results From History Study Of Patients With FAC (RTTNews)
12.02.15	Alnylam Pharma Q4 Loss Narrows (RTTNews)
21.01.15	ALNY Prices Offering At $95/Share (RTTNews)
12.01.15	Alnylam Pharma Announces Updated Results From Phase 1 Study Of ALN-AT3 (RTTNews)
09.01.15	Alnylam Pharma, Isis Pharma Sign New Agreement In RNA Therapeutics (RTTNews)
08.01.15	Alnylam Pharma Launches "Alnylam 2020" Guidance - Quick Facts (RTTNews)
12.12.14	Alnylam Pharma Announces Pipeline Growth Strategy For RNAi Therapeutics (RTTNews)
14.11.14	Alnylam Pharma Announces Positive Initial Phase 2 Data With Revusiran (RTTNews)
14.10.14	Tekmira's Partner Announces Positive Clinical Data For LNP-Enabled Patisiran (RTTNews)
13.10.14	Alnylam Announces Data From Patisiran Phase 2 OLE Study In Patients With FAP (RTTNews)
07.08.14	Alnylam Gets Orphan Drug Designations In European Union For ALN-AT3 (RTTNews)
11.05.14	Alnylam Pharma Presents Key Scientific Data On ESC-GalNAc-Conjugate Technology (RTTNews)
08.05.14	Alnylam Pharma Q1 Loss Widens - Quick Facts (RTTNews)
14.02.14	Alnylam Pharma Q4 Loss Narrowed - Quick Facts (RTTNews)
14.01.14	Isis To Receive $7.5 Mln From Alnylam-Genzyme Alliance (RTTNews)
13.01.14	Genzyme Expands Alliance With Alnylam Pharma, To Invest $700 Mln For 12% Stake (RTTNews)
13.01.14	Alnylam Pharma, Genzyme Form New RNAi Therapeutics Alliance - Quick Facts (RTTNews)
13.01.14	Alnylam Pharma To Buy Merck's Wholly Owned Subsidiary Sirna Therapeutics (RTTNews)
13.01.14	ALNY Opens Wallet, MNKD Gets FDA Panel Date, STEM Keeps Growing (RTTNews)
16.12.13	Alnylam Pharma Begins Pilot Phase II Study With ALN-TTRsc (RTTNews)
09.12.13	Alnylam Presents New Pre-clinical Data On ALN-CC5 - Quick Facts (RTTNews)
25.11.13	Alnylam Earns $7 Mln Milestone Payment From Genzyme On Patisiran Achievement (RTTNews)
11.11.13	Alnylam Gets Fast Track Status For Patisiran To Treat ATTR Patients With FAP (RTTNews)
15.10.13	Upcoming Financial Results Schedules, Clinical Studies and Trials, and New Appointments - Research Report on BioMarin, Alnylam, Aegerion, Omeros, and Tesaro (PR Newswire)
07.10.13	Clinical Study Updates, Trial Enrollments, NDA Submissions, Partnerships, and Formation of New Subsidiaries - Research Report on BioMarin, Alnylam, Vertex, Illumina, and Intrexon (PR Newswire)
03.10.13	Alnylam: ALN-PCS Phase I Study Results Published In The Lancet (RTTNews)
01.10.13	ACRX Files Zalviso NDA, BGMD Gets A Booster, UK's NICE Turns Nice To PSDV (RTTNews)
30.09.13	Alnylam Pharma Completes Enrollment Of Phase II Clinical Trial With ALN-TTR02 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	28.46	2.63 %	K V
Swiss Life Hldg	712.60	1.86 %	K V
Part Grp Hldg	1’245.50	1.26 %	K V
Zurich Insur Gr	545.00	1.15 %	K V
Swiss Re	132.70	1.14 %	K V
Givaudan	3’945.00	-0.53 %	K V
Geberit	511.20	-0.66 %	K V
Alcon	76.38	-0.68 %	K V
Sika	212.90	-1.34 %	K V
CieFinRichemont	134.25	-2.65 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alnylam Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten